Form D · Pharmaceuticals
Aviv Pharma Inc.
Reno, NV · CIK 0002005438
Offering snapshot reported Dec 28, 2023 · SEC filing
- Reported sold
- $2.25M Offering amount: $4M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Dec 15, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 28, 2023 | Initial | $2,252,517 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-501052
Source: Form D, filed Dec 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Philip Arthur Epstein | Director, Executive |
| Jeffrey Alan Glazer | Director, Executive |
| Ricardo Alberto Hungria | Director |
| Robert Rene Rabalais | Director |
| Jeffrey David Rosenberg | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
401 Ryland Street Suite 200 A
Reno, NV, 89502
Reno, NV, 89502